Thyroid hormone antagonists: Potential medical applications and structure activity relationships

Current Medicinal Chemistry

Volumn 16, Issue 25, 2009, Pages 3258-3266

  Malm, Johan ^a   Färnegårdh, Mathias ^b   Grover, Gary J ^c   Ladenson, Paul W ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Karo Bio   (Sweden)

^c Eurofins Medinet Inc   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amiodarone; Design strategy; Hyperthyroidism; Structure activity relationship; Thyroid hormone antagonist; Thyroid hormone receptor; Thyrotoxicosis; X ray structure

Indexed keywords

1 (4 HEXYLPHENYL)PROPENONE; 3 (3,5 DIBROMO 4 CYCLOHEXYLMETHOXYPHENYL)PROPIONIC ACID; 3 [3,5 DIBROMO 4 (3 BROMOBENZYLOXY)PHENYL]PROPIONIC ACID; 3 DIMETHYLAMINO 1 (4 HEXYLPHENYL)PROPAN 1 ONE; [4 [1 (4 HYDROXY 3 ISOPROPYLPHENYL)BUT 2 ENYL] 3,5 DIMETHYLPHENOXY]ACETIC ACID; [4 [4 HYDROXY 3 ISOPROPYL 5 (4 NITROPHENYL)BENZYL] 3,5 DIMETHYLPHENOXY]ACETIC ACID; [4 [4 HYDROXY 3 ISOPROPYL 5 (4 NITROPHENYLETHYNYL)BENZYL] 3,5 DIMETHYLPHENOXY]ACETIC ACID; [[(BUTYL METHYLCARBAMOYL)(4 HYDROXY 3 ISOPROPYLPHENYL)UNDECYL]DIMETHYLPHENOXY]ACETIC ACID; AMIODARONE; ANTITHYROID AGENT; CARBIMAZOLE; DEETHYLAMIODARONE; DRONEDARONE; GC 14; KB 130015; LIOTHYRONINE; LIVER X RECEPTOR; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NH 3; O (4 HYDROXY 3,5 DIISOPROPYLPHENYL)TYROSINE; PERCHLORATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROPYLTHIOURACIL; RADIOACTIVE IODINE; RALOXIFENE; RETINOID X RECEPTOR; THIAMAZOLE; THYROID HORMONE ANTAGONIST; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; THYROXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGRANULOCYTOSIS; ANTIARRHYTHMIC ACTIVITY; ARTHRALGIA; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GENE EXPRESSION; HEART PALPITATION; HEAT INTOLERANCE; HEPATITIS; HORMONE ACTION; HUMAN; LOW DRUG DOSE; MUSCLE WEAKNESS; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PRURITUS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THYROTOXICOSIS; TREMOR; WEIGHT REDUCTION;

ANIMALS; ANTITHYROID AGENTS; HUMANS; LIGANDS; MOLECULAR STRUCTURE; RECEPTORS, THYROID HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349609525     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788803277     Document Type: Review

References (80)

1. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science, 1988, 240, 889-895.
2. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R.M. The nuclear receptor superfamily: the second decade. Cell, 1995, 83, 835-839. (Pubitemid 126663112)
3. Ribeiro, R.C.; Kushner, P.J.; Baxter, J.D. The nuclear hormone receptor gene superfamily. Ann. Rev. Med., 1995, 46, 443-453.
4. Lazar, M.A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr. Rev., 1993, 14, 184-193. (Pubitemid 23118416)
5. Yen, P.M. Physiological and molecular basis of thyroid hormone action. Phys. Rev., 2001, 81, 1097-1142.
6. Ladenson, P.W. In Diagnosis of Thyrotoxicosis. Braverman LE, Utiger RD, Eds. The Thyroid. 9th ed. Philadelphia: JB Lippincott Co., 2005, pp. 659-665.
7. Johansson, C.; Vennström, B.; Thoren, P. Evidence that decreased heart rate in thyroid hormone receptor-alpha1-deficient mice is an intrinsic defect. Am. J. Physiol., 1998, 275, R640-646. (Pubitemid 28390140)
8. Forrest, D.; Vennström, B. Functions of thyroid hormone receptors in mice. Thyroid, 2000, 10, 41-52. (Pubitemid 30090364)
9. Takeda, K.; Sakurai, A.; DeGroot, L.J.; Refetoff, S.J. Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene. Clin. Endocrinol. Metab., 1992, 74, 49-55.
10. Steinmetz, A.C.; Renaud, J.P.; Moras, D. Binding of ligands and activation of transcription by nuclear receptors. Annu. Rev. Biophys. Biomol. Struct., 2001, 30, 329-359. (Pubitemid 32566167)
11. Bourguet, W.; Germain, P.; Gronemeyer, H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci., 2000, 21, 381-388. (Pubitemid 30767867)
12. Wagner, R.L.; Apriletti, J.W.; McGrath, M.E.; West, B.L.; Baxter, J.D.; Fletterick, R.J. A structural role for hormone in the thyroid hormone receptor. Nature, 1995, 378, 690-697. (Pubitemid 3009997)
13. Darimont, B.D.; Wagner, R.L.; Apriletti, J.W.; Stallcup, M.R.; Kushner, P.J.; Baxter, J.D., Fletterick, R.J.; Yamamoto, K.R. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev., 1998, 12, 3343-3356. X-ray coordinates ID reported at RCSB PDB as 1bsx.
14. Wagner, R.L.; Huber, R.B.; Shiau, A.K.; Kelly, A.; Cunha Lima, S.T.; Scanlan, T.S.; Apriletti, J.W.; Baxter, J.D.; West, B.L.; Fleta-All Fletterick, R.J. Hormone selectivity in thyroid hormone receptors. Mol. Endocrinol., 2001, 15, 398-410.
15. Dow, R.L.; Schnelier, S.R.; Paight, E.S.; Hank, R.F.; Chiang, P.; Cornelius, P.; Lee, E.; Newsome, W.P.; Swick, A.G.; Spitzer, J.; Hargrove, D.M.; Patterson, T.A.; Pandit, J.; Chrunyk, B.A.; LeMotte, P.K.; Danley, D.E.; Rosner, M.H.; Ammirati, M.J.; Simons, S.P.; Schulte, G.K.; Tate, B.F.; DaSilva-Jardine, P. Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics. Bioorg. Med. Chem. Lett., 2003, 13, 379-382. X-ray coordinates ID reported at RCSB PDB as 1n46. (Pubitemid 36259696)
16. Ye, L.; Li, Y.L.; Mellstrom, K.; Mellin, C.; Bladh, L.G.; Koehler, K.; Garg, N.; Garcia Collazo, A.M.; Litten, C.; Husman, B.; Persson, K.; Ljunggren, J.; Grover, G.; Sleph, P.G.; George, R.; Malm, J. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J. Med. Chem., 2003, 45, 1580-1588. X-ray coordinates ID reported at RCSB PDB as 1nav (TR 1) and 1nax (TRβ1). (Pubitemid 36452328)
17. Hangeland, J.J.; Doweyko, A.M.; Dejneka, T.; Friends, T.J.; Devasthale, P.; Mellstrom, K.; Sandberg, J.; Grynfarb, M.; Sack, J.S.; Einspahr, H.; Färnegardh, M.; Husman, B.; Ljunggren, J.; Koehler, K.; Sheppard, C.; Malm, J.; Ryono, D.E. Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorg. Med. Chem. Lett., 2004, 14, 3549-3553. X-ray coordinates ID reported at RCSB PDB as 1r6g. (Pubitemid 38744530)
18. Sandler, B.; Webb, P.; Apriletti, J.W.; Huber, R.R.; Togashi, M.; Cunha Lima, S.T.; Juric, S.; Nilsson, S.; Wagner, R.; Fletterick, R.J.; Baxter, J.D. Thyroxine-thyroid hormone receptor interactions. J. Biol. Chem., 2004, 279, 55801-55808. X-ray coordinates ID reported at RCSB PDB as 1xzx and 1y0x.
19. Borngraeber, S.; Budny, M.J.; Chiellini, G.; Cunha-Lima, S.T.; Togashi, M.; Webb, P.; Baxter, J.D.; Scanlan, T.S.; Fletterick, R.J. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Natl. Acad. Sci. USA, 2003, 100, 15358-15363.
20. Garcia Collazo, A.M.; Koehler, K.F.; Garg, N.; Färnegårdh, M.; Husman, B.; Ye, L.; Ljunggren, J.; Mellström, K.; Sandberg, J.; Grynfarb, M.; Ahola, H.; Malm, J. Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. Bioorg. Med. Chem. Lett., 2006, 16, 1240-1244. (Pubitemid 43142998)
21. Bourguet, W.; Ruff, M.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature, 1995, 375, 377-382.
22. Brzozowski, A. M.; Pike, A.C.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G.L.; Gustafsson, J.Å.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 1997, 389, 753-758. (Pubitemid 27458965)
23. Xu, H.E.; Stanley, T.B.; Montana, V.G.; Lambert, M.H.; Shearer, B.D.; Cobb, J.E.; McKee, D.D.; Galardi, C.M.; Plunket, K.D.; Nolte, R.T.; Parks, D.J.; Moore, J.T. Kliewer, S.A.; Willson, T.M.; Stimmel, J.B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature, 2002, 415, 813-817. X-ray coordinates ID reported at RCSB PDB as 1kkq.
24. Färnegårdh, M.; Bonn, T.; Sun, S.; Ljunggren, J.; Ahola, H.; Wilhelmsson, A.; Gustafsson, J.A.; Carlquist, M. The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J. Biol. Chem., 2003, 40, 38821-38828. (Pubitemid 37229066)
25. Xu, H.E., Lambert, M.H.; Montana, V.G.; Plunket, K.D.; Moore, L.B.; Collins, J.L.; Oplinger, J.A.; Kliewer, S.A.; Gampe, Jr. R.T.; McKee, D.D.; Moore, J.T.; Willson, T.M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA, 2001, 24, 13919-13924. X-ray coordinates ID reported at RCSB PDB as 1k7l.
26. Martínez, L.; Sonoda, M.T.; Webb, P.; Baxter, J.D.; Skaf, M.S.; Polikarpovz, I. Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors. Biophys. J., 2005, 89, 2011-2023. (Pubitemid 41233556)
27. Togashi, M.; Borngraeber, S.; Sandler, B.; Fletterick, R.J.; Webb, P.; Baxter, J.D. Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design. J. Steroid Biochem. Mol. Biol., 2005, 93, 127-137.
28. Martínez, L.; Polikarpov, I.; Skaf, M.S. Only subtle protein conformational adaptations are required for ligand binding to thyroid hormone receptors: simulations using a novel multipoint steered molecular dynamics approach. J. Phys. Chem. B., 2008, 112, 10741-10751.
29. Cooper, D.S. Antithyroid drugs N. Engl. J. Med., 2005, 352, 905-917.
30. Schussler-Fiorenza, C.M.; Bruns, C.M.; Chen, H. The surgical management of Graves' disease. Surg. Res., 2006, 133, 207-214.
31. Franklyn, J.A. The management of hyperthyroidism. N. Engl. J. Med., 1994, 330, 1731-1738.
32. Jorgensen, C.H. In Hormonal Proteins and Peptides, Thyroid hormones and analogs. II. Structure-Activity Relationships, Li, C.H., Ed. Academic Press: New York, 1978, Vol. 6, pp. 107-204.
33. Ryono, D.E.; Grover, G.J.; Mellström, K. In Thyroid Hormones and Thyromimetics. Burger's Medicinal Chemistry and Drug Discovery. Chapter 12. Abraham, Ed.; 2003, Vol. 3.
34. Leeson, P.D.; Underwood, A.H. In Comprehensive Medicinal Chemistry, Thyroid Hormone Receptors, Emmett, J.C., Ed.; Pergamon Press: Oxford, London, 1990, Vol. 3, pp. 1145-1173.
35. Reid, D.G.; Maclachlan, L.K.; Voyle, M.; Leeson, P.D. A proton and fluorine-19 nuclear magnetic resonance and fluorescence study of the binding of some natural and synthetic thyromimetics to prealbumin (transthyretin). J. Biol. Chem., 1989, 264, 2013-2023.
36. Shulkin, B.L.; Bolger, M.B.; Utiger, R.D. Thyroid hormone analog inhibition of hepatic 5'-iodothyronine deiodinase activity. J. Endocrinol. Invest., 1988, 11, 657-661.
37. Koehrle, J.; Auf'mkolk, M.; Rokos, H.; Hesch, R.D.; Cody, V. Rat liver iodothyronine monodeiodinase. Evaluation of the iodothyronine ligand-binding site. J. Biol. Chem., 1986, 261, 11613-11622.
38. Tropsha, A.E.; Rakhmaninova, A.B.; Iaguzhinskii, L.S. Configuration and properties of a binding site for thyroid hormones on a specific receptor Bioorg. Khim., 1984, 10, 483-492.
39. Bolger, M.B.; Jorgensen, E.C. Molecular interactions between thyroid hormone analogs and the rat liver nuclear receptor. Partitioning of equilibrium binding free energy changes into substituent group interactions. J. Biol. Chem., 1980, 255, 10271-10278.
40. Dietrich, S.W.; Bolger, M.B.; Kollman, P.A.; Jorgensen, E.C. Thyroxine analogues. 23. Quantitative structure-activity correlation studies of in vivo and in vitro thyromimetic activities. J. Med. Chem., 1977, 20, 863-880.
41. Koerner, D.; Schwartz. H.L.; Surks, M.L.; Oppenheimer, J.H. Binding of selected iodothyronine analogues to receptor sites of isolated rat hepatic nuclei. High correlation between structural requirements for nuclear binding and biological activity. J. Biol. Chem., 1975, 250, 6417-6423.
42. Baxter, J.D.; Goede, P.; Apriletti, J.W.; West, B.L.; Feng, W.; Mellström, K.; Fletterick, R.J.; Wagner, R.L.; Kushner, P.J.; Ribeiro, R.C.J.; Webb, P.; Scanlan, T.S.; Nilsson, S. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology, 2002, 143, 517-524. (Pubitemid 34107205)
43. Chiellini, G.; Apriletti, J.W.; Yosihhara, H.A.; Baxter, J.D.; Ribeiro, R.C.J.; Scanlan, T.S. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem. Biol., 1998, 5, 299-306.
44. Chiellini, G.; Nguyen, N. H.; Apriletti, J.W.; Baxter, J.D.; Scanlan, T.S. Synthesis and biological activity of novel thyroid hormone analogues: 5′-aryl substituted GC-1 derivatives. Bioorg. Med. Chem. Lett., 2002, 10, 333-346.
45. Nguyen, N.H.; Apriletti, J.W.; Lima, S.T.C.; Webb, P.; Baxter, J.D.; Scanlan, T.S. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J. Med. Chem., 2002, 45, 3310-3320.
46. Lim, W.; Nguyen, N.H.; Yang, H.Y.; Scanlan, T.S.; Furlow, J.D. A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J. Biol. Chem., 2002, 277, 35664-35670. (Pubitemid 35052476)
47. Grover, GJ, Dunn, C, Nguyen, NH, Boulet, J, Dong, G, Domogauer, J, Barbounis, P, Scanlan, TS. Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats. J. Pharmacol. Exp. Ther., 2007, 322(1), 385-390 (Pubitemid 46956356)
48. Borngraeber, S.; Budny, M.J.; Chiellini, G.; Cunha-Lima, S.T.; Togashi, M.; Webb, P.; Baxter, J.D.; Scanlan, T.S.; Fletterick, R.J. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Natl. Acad. Sci. USA, 2003, 100, 15358-15363
49. 1).
50. While this type of antagonism has been referred to as "passive", we prefer the term "indirect" to avoid confusion with active vs. competitive or "passive" antagonism that has been used to describe antagonism of e.g. the glucocorticoid (GR) receptor. The rationale for making this distinction has been outlined in reference [54].
51. Shiau, A.K.; Barstad, D.; Radek, J.T.; Meyers, M.J.; Nettles, K.W.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A.; Agard, D.A.; Greene, G.L. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol., 2002, 9, 359-364.
52. Singh, S.M.; Gauthier, S.; Labrie, F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr. Med. Chem., 2000, 7, 211-247. (Pubitemid 30396447)
53. Souque, A.; Fagart, J.; Couette, B.; Davioud, E.; Sobrio, F.; Marquet A.; Rafestin-Oblin, M.E. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology, 1995, 136, 5651-5658.
54. Hedfors, Å.; Appelqvist, T.; Carlsson, B.; Bladh, L.-B.; Litten, C.; Agback, P.; Grynfarb, M.; Koehler, K.F.; Malm, J. Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J. Med. Chem., 2005, 48, 3114-3117. (Pubitemid 40628029)
55. Malm, J.; Gordon, S.; Brandt, P.; Carlsson, B.; Agback, P.; Bäckbro Saeidi, A.; Sandberg, J. Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorg. Med. Chem. Lett., 2007, 17, 2018-2021. (Pubitemid 46389581)
56. Singh, B.N.; Vaughan Williams, E.M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br. J. Pharmacol., 1970, 39, 657-667.
57. Latham, K.R.; Selitti, D.F.; Goldstein, R.E. Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. J. Am. Coll. Cardiol., 1987, 7, 472-476.
58. Norman, M.F.; Lavin, T.A. Competition of thyroid hormone action by amiodarone in rat pituitary tumor cells. J. Clin. Invest., 1989, 83, 306-313. (Pubitemid 19048437)
59. Bosch, R.F.; Li, G-R.; Gaspo, R.; Nattel, S. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes. J. Pharmacol. Exp. Ther., 1999, 289,156-165. (Pubitemid 29156024)
60. Singh, B.N. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am. J. Cardiol., 1996, 78, 41-53.
61. Kodama, I.; Kamiya, K.; Toyama, J. Cellular electropharmacology of amiodarone. Cardiovasc. Res., 1997, 35, 13-29.
62. Drvota, V.; Carlsson, B.; Häggblad, J.; Sylven, C. Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect. J. Cardiovasc. Pharmacol., 1995, 26, 222-226.
63. van Beeren, H.C.; Bakker, O.; Wiersinga, W.M. Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone alpha 1-receptor protein. Mol. Cell. Endocrinol., 1995, 112, 15-19.
64. Bakker, O.; van Beeren, H.C.; Wiersinga, W.M. Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta 1-receptor protein. Endocrinology, 1994, 134, 1665-1670. (Pubitemid 24110721)
65. van Beeren, H.C.; Jong, W.M.; Kaptein, E.; Visser, T.J.; Bakker, O.; Wiersinga, W.M. Dronerarone acts as a selective inhibitor of 3,5,3′-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. Endocrinology, 2003, 144, 552-558.
66. Carlsson, B.; Singh, B.N.; Temciuc, M.; Nilsson, S.; Li, Y.L.; Mellin, C.; Malm, J. Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. J. Med. Chem., 2002, 45, 623-630.
67. van Beeren, H.C.; Bakker, O.; Wiersinga, W.M. Structure-function relationship of the inhibition of the 3,5,3′-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. Endocrinology, 1996, 137, 2807-2814. (Pubitemid 126425496)
68. Chalmers, D.K, Munro, S.L.A.; Iskander, M.N.; Craik, D.J. Models for the binding of amiodarone to the thyroid hormone receptor. J. Comp. Aided Mol. Des., 1992, 6, 19-31.
69. Ha, H.R.; Stieger, B.; Grassi, G.; Altorfer, H.R.; Follath, F. Structure-effect relationships of amiodarone analogues on the inhibition of thyroxine deiodination. Eur. J. Clin. Pharmacol., 2000, 55, 807-814. (Pubitemid 30201762)
70. Schröder-van der Elst, J.P.; van der Heide, D. Thyroxine, 3,5,3′-triiodothyronine, and 3,3′,5′-triiodothyronine concentrations in several tissues of the rat: effects of amiodarone and desethylamiodarone on thyroid hormone metabolism. Endocrinology, 1990, 127, 1656-1664. (Erratum in Endocrinology, 1991, 128, 393) (Pubitemid 20315223)
71. Norman, M.F.; Lavin, T.N. Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells. J. Clin. Invest., 1989, 83, 306-313. (Pubitemid 19048437)
72. Bowler, J.; Lilley, T.J.; Pittam, J. D.; Wakeling, A.E. Novel steroidal pure antiestrogens. Steroids, 1989, 54, 71-99.
73. Wakeling, A.E.; Bowler, J. Steroidal pure antioestrogens. J. Endocrinol., 1987, 112, R7-10.
74. Yoshihara, H.A.; Apriletti, J.W.; Baxter, J.D.; Scanlan, T.S. A designed antagonist of the thyroid hormone receptor. Bioorg. Med. Chem. Lett., 2001, 11, 2821-2825.
75. Geistlinger, T.R.; Guy, R.K. An inhibitor of the interaction of thyroid hormone receptor beta and glucocorticoid interacting protein 1. J. Am. Chem. Soc., 2001, 123, 1525-1526.
76. Geistlinger, T.R.; Guy, R.K. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc., 2003, 125, 6852-6853.
77. Arnold, L.A.; Estébanez-Perpiñá, E.; Togashi, M.; Shelat, A.; Ocasio, C.A.; McReynolds A.C.; Nguyen, P.; Baxter, J.D.; Fletterick, R.J.; Webb, P.; Guy, R.K. A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci. STKE, 2006, 341, l3.
78. Arnold, L.A.; Estébanez-Perpiñá, E.; Togashi, M.; Jouravel, N.; Shelat, A.; McReynolds A.C.; Mar E, Nguyen, P.; Baxter, J.D.; Fletterick, R.J.; Webb, P.; Guy, R.K. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem., 2005, 280, 43048-43055 (Pubitemid 43049270)
79. Arnold, L.A.; Kosinski, A.; Estébanez-Perpiñá, E.; Fletterick, R.J.; Guy, R.K. Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J. Med. Chem., 2007, 50, 5269-5280. (Pubitemid 350057839)
80. Li, Y.-L.; Litten, C.; Koehler, K.F.; Mellström, K.; Garg, N.; Garcia Collazo, A.M.; Färnegård, M.; Grynfarb, M.; Husman, B.; Sandberg, J.; Malm, J. Thyroid receptor ligands. Part 4: 4′-amido bioisosteric ligands selective for the thyroid hormone receptor beta. Bioorg. Med. Chem. Lett., 2006, 16, 884-886. (Pubitemid 43059844)